
Daniel Lorenzatti, MD.
@danilorenzatti
Cardiologist | Multimodality Cardiovascular Imager | Advanced Cardiac Imaging @MontefioreNYC | Scientific Advisor @INCIC_Chile | SoMe Editor @PCVDJournal
ID: 154640834
11-06-2010 20:21:44
3,3K Tweet
3,3K Followers
597 Following


Coronary artery build-up linked to high-volume exercise: What cardiologists need to know beckershospitalreview.com/cardiology/cor… Ahmed Abdelaziz, MD Montefiore Heart Montefiore Health System Carl Lavie



Colchicine for Secondary Prevention in Established ASCVD: A Systematic Review and Meta-Analysis academic.oup.com/eurjpc/article… Ahmed Abdelaziz, MD Daniel Lorenzatti, MD. Ashley Radparvar, MD Toshiki Kuno, MD, PhD, FESC, FSCAI Annalisa Filtz Carl Lavie Dr. Martha Gulati ♥️🫀❤️🩹🇨🇦 Dr. Deepak L. Bhatt Salim Virani Michael D. Shapiro Montefiore Health System


🧲What do you think of #WhyCMR in the evaluation of pHTN patients? 🤔 See the editorial we wrote with Manish Motwani on the topic.. Society for Cardiovascular Magnetic Resonance



“CMR phenotyping can be used immediately in clinical practice to identify patients with suspected cardiac sarcoidosis who would benefit from a primary prevention ICD," said Chetan Shenoy. Read more about how this can prevent life-threatening ventricular arrhythmias:




June is Cardiomyopathy Awareness Month! 💙 #whyCMR plays a 🔑role in diagnosing and managing cardiomyopathy. 🫀 Explore Society for Cardiovascular Magnetic Resonance patient-friendly website heartmri.org. #HeartHealth #HeartMonth youtu.be/71BW3bo96XA youtu.be/r7A6m6B2Yq8 youtu.be/uNBO_DG_MWg



🧠📊 AI-guided CCTA identifies plaque in ~96–97% of patients—but a PAV ≤2.6% signals low long-term ACS risk. Validated across two cohorts, this cut-off may aid safer, smarter risk stratification. #AI #CCTA #Cardiology #PlaqueBurden 🔗 doi.org/10.1093/ehjci/… European Society of Cardiology Journals


Urgent surgery vs fibrinolytic therapy for left-sided prosthetic valve thrombosis. Read the results of a randomized trial published in #EHJ 👉 ow.ly/A4pX50Wl1i0 Rocco Montone EHJ Editor-in-Chief



💯, we need to revise the famous CAST trial John Mandrola, MD